Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi and Alnylam report positive data from amyloidosis drug trial

Sanofi and Alnylam report positive data from amyloidosis drug trial

22nd September 2017

Sanofi and Alnylam have announced new clinical trial data demonstrating the benefits patisiran can offer in the treatment of hereditary ATTR amyloidosis with polyneuropathy.

Data from the phase III APOLLO trial has shown that the investigational RNAi therapeutic was able to deliver a highly significant reduction in neuropathy progression and quality of life improvements at 18 months relative to placebo.

APOLLO enrolled 225 patients with polyneuropathy, representing 39 genotypes of the disease, across 44 study sites in 19 countries around the world. The overall safety profile of patisiran was also shown to be encouraging.

Based on these positive results, Alnylam will file for US regulatory approval of the drug in late 2017, with further applications expected to follow.

Sanofi Genzyme is preparing regulatory filings for patisiran in Japan, Brazil and other countries to begin in the first half of 2018, with Alnylam handling sales in the US, Canada and western Europe.

Dr Elias Zerhouni, president for global research and development at Sanofi, said: "This is a significant milestone that supports our belief that RNAi therapeutics have the potential to become an innovative new class of medicines for patients with rare genetic diseases."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.